# EN｜Screening Is Not “Get It and Be Reassured”: The Three Trade-Offs Behind Early Breast Cancer Detection
Here we step into Part 2 of this series—”Noticing.” Part 1 showed that breast cancer is not one disease but a collection of different personalities, and that it is a cancer whose path opens up when caught early. The tool that actually delivers that “catching early” is screening.
But screening is not the simple story of “do it and be reassured.” Yes, breast cancer screening is one of the few measures proven to lower mortality when done properly. Yet it also carries harms: radiation exposure, false positives (being flagged when there is no cancer), and overdiagnosis (finding cancers that would never have caused harm). To speak only of the benefits is dishonest; to overstate the harms and drive people away from screening is dangerous.
In this installment, we weigh those benefits and harms honestly, then answer the practical question: when, who, and how should one be screened? We keep the hard ideas gentle—but we don’t hide the inconvenient numbers. That honesty is the foundation for making calm decisions about your own body.
Information about screening tends to swing to two extremes. One holds that “the more tests, the more often, the safer.” The other holds that “radiation and overdiagnosis are frightening, so I’d rather not be screened.” Both see only half of what screening is. Screening is a tool of probabilities, where benefit and harm live together. That is exactly why a regret-free choice comes not from feeling but from numbers—and not from one number alone, but from holding both in view at once.
What Mammography Actually Sees — Its Strengths and Blind Spots
At the center of breast cancer screening is the mammogram, an X-ray made specifically for the breast. The breast is compressed between two plates and spread thin, then imaged with a low dose of X-rays. The pressure—uncomfortable as it is—serves a purpose: it keeps the radiation dose low while spreading overlapping tissue so fine details can be seen.
What mammography does best is detect microcalcifications—tiny calcium deposits. In the very earliest cancers, especially those still confined within the duct (non-invasive disease), these sand-like flecks can be the only clue. A cancer with no lump to feel and no symptoms—mammography can render it visible. That is why it can lower mortality.
But it has blind spots. In breasts rich in glandular tissue, which appears white on the image, a lump—also white—can hide against the background (the “dense breast,” discussed below). Picture searching for a white object on a field of snow, and the difficulty becomes vivid. Mammography is not all-powerful; it is a tool with both a strong suit and a weak one. Start there.
What matters here is that the evidence for screening lowering mortality was built over decades of large comparative studies. Groups who were screened and groups who were not were followed for years, and fewer breast cancer deaths in the former were confirmed—through that patient verification, mammography earned its place as a recommended screen. Put the other way: however sensitive a new test may be, it cannot casually become the population standard until it is proven to lower mortality. That very caution is the etiquette of screening.
Benefits and Harms: Three Trade-Offs
When thinking about screening, three scales must be weighed.
① Radiation exposure Mammography uses X-rays, so there is some radiation. But the dose is tiny—comparable to a few months of the natural background radiation we absorb daily. The benefit of screening (lives saved through early detection) is estimated to greatly outweigh this risk. At recommended intervals, exposure is not something to fear.
② False positives Being told “possible abnormality,” then learning after further testing that there was no cancer—that is a false positive. It happens more often than people expect. U.S. modeling estimates that biennial screening from age 40 across a lifetime yields roughly 1,376 false positives per 1,000 women. The younger the breast, the denser the tissue, and the higher the false-positive rate. A false positive is not life-threatening, but the anxiety before re-testing, the extra imaging, and sometimes a needle biopsy carry real psychological and physical cost.
③ Overdiagnosis The hardest to grasp—and the most important—is overdiagnosis: finding a cancer that, left alone, would never have caused symptoms or threatened life. This is not misdiagnosis. It is a real cancer, but one so slow or so stalled that treating it was never necessary. An estimated 10–30% of screen-detected breast cancers (some recent estimates put it at 11–19%) are overdiagnosed. The trouble is that today’s medicine cannot tell in advance which ones these are. As a result, some people undergo surgery or treatment they may never have needed.
What makes overdiagnosis so vexing is that the person who experiences it can never feel it. Someone treated and now well will believe, “Screening saved me.” Yet among them, statistically, must sit some for whom nothing would have happened either way—and which person that was is something neither they nor their doctor will ever know. Overdiagnosis is invisible in any individual’s story; it appears only in the statistics of the group. That property makes the debate harder still. It should be received not as a reason to abandon screening, but as a reason to redesign it wisely.
Here, too, the benefit side deserves a sense of scale rather than a feeling. Pooled analyses of large studies estimate that regular mammographic screening lowers death from breast cancer by roughly a fifth. That is not a dramatic “zero to a hundred” figure, but given how many people are involved, it amounts to a substantial number of lives saved across a population. Note, too, that this benefit shifts with age: in older groups, where breast cancer is more common, the same screen catches more genuine cancers, so benefit more readily exceeds harm. In younger groups, where cancer is rarer and false positives more frequent, the scale tips toward harm. So the question of “from what age” rests not on emotion but on this very crossing point of benefit and harm.
Laid out honestly, screening has a clear shape: the benefits outweigh the harms, but the harms are not zero. That is exactly why “more is better” is the wrong instinct. The key is choosing the way of screening where benefit most exceeds harm. That optimal point shifts slightly with age, breast density, and one’s own risk. Screening is not a single answer for everyone, but the work of finding the approach that fits you. And the fact that harms exist is not a reason to avoid screening. If anything, the person who understands what those harms are can stay calm when a recall notice arrives, take the next step without being swallowed by excessive fear—knowing is itself a preparation for a wise relationship with screening.
Tomosynthesis and Dense Breasts — A New Answer to “Hard to See”
How has technology answered mammography’s weakness—the trouble seeing through dense tissue?
One advance is tomosynthesis (3D mammography). Where conventional mammography flattens the breast into a single plane, tomosynthesis captures multiple images at different angles and reconstructs the breast as thin slices—much like a CT scan sectioning the body—so lumps once hidden by overlap become easier to see. As a result, cancer detection rises slightly while recall-driven false positives can fall. Both “the power to find” and “the power not to call back needlessly” improve a little at once—in the language of our scales, one of the few advances that can move both pans in a good direction. It is now the mainstream standard at most mammography centers in many high-income countries.
But tomosynthesis is not all-powerful either. Its radiation dose is comparable to conventional imaging—or, without synthesized-image techniques, slightly higher—and it does not entirely erase the weakness against dense tissue. It is an upgrade that lifts conventional mammography, not a magic single-handed solution to the dense-breast problem discussed next. Calibrating one’s expectations correctly matters.
The other key idea is dense breasts. These are breasts with a high proportion of glandular tissue that appears white throughout on a mammogram. Density is not a disease, but a white lump against a white background lowers mammographic sensitivity, and high density itself modestly raises breast cancer risk.
What matters is having a way to know whether your breasts are dense. In the United States, since September 2024, every person who receives a mammogram must be told their breast density nationwide. “Your breast tissue is dense. Dense tissue makes cancer harder to find on a mammogram and also raises risk. Talk to your provider about additional imaging.” Such notification has become the standard, replacing a patchwork of differing state rules.
For people with dense breasts, supplemental options include ultrasound and MRI. Ultrasound uses no radiation, is inexpensive, and can catch lumps within dense tissue. MRI is more sensitive still and is recommended for those at particularly high risk, such as carriers of BRCA mutations—but its cost and higher false-positive rate mean it is not for everyone. Which supplemental test fits depends on density, risk, and what is locally available, so it is a conversation to have with a clinician.
One caution: do not leap to “dense breast equals danger.” Dense breasts are an utterly common trait, and density itself is not a disease; the rise in risk it brings is modest. What matters is the calm next step—knowing you are dense, sharing the premise that “mammography alone can miss things,” and considering supplemental imaging if warranted. The true value of a notification rule is not to hand out anxiety, but to open for everyone an informed doorway to a conversation with their clinician.
Self-Exam and Breast Awareness — Placing Them Correctly
“Does checking your own breasts make any difference?” It’s a common question, and the answer carries nuance.
Formal, scheduled breast self-examination was once widely promoted, but large studies found it did not lower mortality and tended instead to increase anxiety over benign lumps and unnecessary tests. It is no longer recommended as a substitute for screening.
What is emphasized internationally instead is breast awareness: not a quota to “check once a month by a fixed routine,” but the everyday habit of knowing how your breasts normally look and feel, and seeking care without delay when something differs (a lump, dimpling, skin or nipple changes, discharge). A habit, not a duty. A natural noticing, not an anxious inspection. This is what fills the gap between one screening and the next.
What does “something differs” look like concretely? Common signs include a newly palpable lump, a dimple or pucker of the skin on just one side, an inward-turning or changed nipple, blood-tinged discharge, or an eczema-like change of the areola that will not heal. Breasts that swell or feel mildly tender around the menstrual cycle are usually physiological and need no alarm. The point is to hold a baseline—”how I normally am”—because only someone who knows their normal can notice a change.
But it must be stressed: breast awareness is no replacement for screening. Screening’s job is to find cancers before any lump can be felt; the two are complementary, not interchangeable. Screening is the net cast “before symptoms appear”; awareness is the net that catches changes arising between one screen and the next. Layering these two nets lowers the odds of a miss—either one alone leaves a gap.
When and Who Should Be Screened
So, the practical conclusion. Current guidance in high-income countries generally recommends regular mammography beginning at age 40, with screening continuing through about age 74. (Intervals vary by country—every one to two years—and the choice in the early 40s often involves a conversation about personal preference and risk.) This is the way of screening with proven mortality benefit. Routine mammography is generally not recommended for women in their 20s and 30s, whose dense tissue raises false positives.
This baseline, however, is for people at average risk with no symptoms. Those at high risk—a strong family history, a known BRCA mutation—may need earlier and more intensive screening, including added MRI. How to estimate risk and weigh inheritance is covered in Vol.2 and Vol.10. And if you have a worrying symptom, do not wait for a scheduled screen—see a clinician promptly. Screening is for people without symptoms; for those with symptoms, the door is clinical evaluation.
It also helps to distinguish two kinds of screening. Organized (population) screening is run as a public system, designed to lower mortality across a whole community. Opportunistic (individual) screening, by contrast, is something a person chooses on their own—often through a private health check—where richer menus such as added ultrasound or MRI can be selected, but the benefit-harm balance is one you take on yourself. Neither is simply “better”; their aims differ. Weighing your own risk and values, and considering supplemental tests with your clinician where warranted, is the proactive stance that defines a modern relationship with screening.
The next installment, Vol.7, moves to exactly what comes after—what to do when you notice a lump. It addresses, in high resolution, the hesitation that arises between noticing and seeking care, the scientific risk of “waiting and watching,” and—on the reassuring side—the fact that benign lumps are extremely common. From “finding” through screening to “noticing” changes in your own body: from here, Part 2 walks alongside the personal journey.
My Thought
The first thing worth saying about screening is an obvious truth: it is neither “do it and be safe” nor “doing it is pointless.” Breast cancer screening reliably lowers mortality, yet it carries harms—radiation, false positives, overdiagnosis. Knowing both sides and steadily following the recommended approach is the choice that serves you best. Avoiding it out of fear, or leaning on it with blind trust, are both suboptimal.
A step deeper, the heart of the screening debate is overdiagnosis. We still cannot reliably tell, at the moment of diagnosis, whether a cancer is one to leave alone or one that will progress. So the intuition that “early detection is always good” carries a real caveat. True progress is not finding more, but stratifying the danger of what we find—separating what must be treated from what need not be. Density-tailored imaging, AI that reads images, and future risk-prediction models are all attempts to move toward this “smarter early detection.” The future of screening lies not in frequency but in precision and personalization—a map this series will draw in its later chapters.
Continue the Series
- Vol.1: Breast Cancer Is Not One Disease (the series’ entry point)
- Previous: Vol.5 | The Three Switches Behind the “Five Faces”
- Next: Vol.7 | When You Find a Lump
Related Reading
If you leave a comment telling us which cancers or conditions you’d like us to cover next, we’ll prioritize them in future features.
Comments